For example, some may start with a low dose for the first month, such as 0.25 mg, and then increase to 0.5 mg or 1 mg over the following months
Research from the STEP clinical trial program demonstrated that weight loss outcomes were dose-dependent, with significantly greater reductions at higher doses
We systematically extracted data on primary outcomes (visual acuity, retinal thickness, disease progression) and secondary outcomes (microvascular changes, inflammatory markers, adverse events), capturing all reported time points and analysis methods
M.MaurerL
K., Mangelsdorf, I., McArdle, H
Note: I do not treat KP, please see my colleagues at Clinic Cutis